Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136829 | 0.88 | TSHR (0.51) | TSHRMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL4136070 | 0.85 | NPSR1 (0.34) | ALDH1A1MEN1CYP1A2KMT2A | |
| SCHEMBL17965675 | 0.80 | TSHR (0.64) | TSHRMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL1471724 | 0.77 | TSHR (0.64) | TSHRMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL1471723 | 0.77 | TSHR (0.57) | TSHRMAPK1ALDH1A1SMN1; SMN2TP53 | |
| Propane SCHEMBL3297482 | 0.74 | TSHR (0.60) | TSHRMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL5510350 | 0.73 | TSHR (0.38) | TSHRMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL4461926 | 0.71 | TSHR (0.59) | TSHRMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL1069813 | 0.70 | TSHR (0.77) | TSHRMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL50007 | 0.69 | TSHR (0.63) | TSHRMAPK1ALDH1A1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137774-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC COMPONENT USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1930327-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC COMPONENT USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137774-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC COMPONENT USING SAME | GJA1, CDH1, OR10J3 | TSHR 4392/4885MAPK1 3021/4885ALDH1A1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.